Content deleted Content added
update links, cats |
|||
Line 64:
Sorafenib is a [[protein kinase inhibitor]] with activity against many [[protein kinase]]s, including [[VEGFR]], [[PDGFR]] and [[RAF kinase]]s.<ref name="pmid18852116">{{cite journal | vauthors = Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M | title = Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | journal = Mol Cancer Ther | volume = 7 | issue = 10 | pages = 3129–40 |date=October 2008 | pmid = 18852116| doi = 10.1158/1535-7163.MCT-08-0013 | doi-access = free }}</ref><ref name=Keeting2009/> Of the RAF kinases, Sorafenib is more selective for [[c-Raf]] than [[B-RAF]].<ref name="pmid18794803">{{cite journal | vauthors = Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M | title = CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations | journal = Oncogene | volume = 28 | issue = 1 | pages = 85–94 |date=January 2009| pmc = 2898184| pmid = 18794803 | doi = 10.1038/onc.2008.362 }}</ref> (See [[BRAF (gene)#Sorafenib]] for details the drug's interaction with B-Raf.)
Sorafenib treatment induces [[autophagy]],<ref name=" pmid = 24213221">{{cite journal | author = Zhang Y | title = Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways. | journal = Mol Med Rep | volume = 9 | issue = 1|date=Jan 2014 | pmid = 24213221| pages = 83–90| doi = 10.3892/mmr.2013.1781 | doi-access = free }}</ref> which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, Sorafenib is also a potent [[soluble epoxide hydrolase]] inhibitor and this activity likely reduces the severity of its adverse effects.<ref>{{cite book |last1=Singh | first1=Nalin | last2=Hammock | first2=Bruce | editor-last1=Offermanns | editor-first1=Stefan |editor-last2=Rosenthal |editor-first2=Walter |title=Encyclopedia of Molecular Pharmacology | publisher=Springer, Cham |date=March 30, 2020 | chapter=Soluble Epoxide Hydrolase |doi = 10.1007/978-3-030-21573-6 | isbn=978-3-030-21573-6}}</ref>
==Medical uses==
| |||